Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma

New England Journal of Medicine

Volumn 334, Issue 4, 1996, Pages 231-238

  Norris, Murray D ^a   Bordow, Sharon B ^a   Marshall, Glenn M ^a   Haber, Paul S ^b   Cohn, Susan L ^c   Haber, Michelle ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c NORTHWESTERN UNIVERSITY   (United States)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NEUROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; PROGNOSIS;

ATP-BINDING CASSETTE TRANSPORTERS; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; INFANT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEUROBLASTOMA; P-GLYCOPROTEIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 0030031845     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199601253340405     Document Type: Article

References (51)

1. Crist WM, Kun LE. Common solid tumors of childhood. N Engl J Med 1991;324.461-71.
2. Brodeur GM, Castleberry RP. Neuroblastoma In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology 2nd ed. Philadelphia. J B. Lippincott, 1993:739-67
3. Brodeur GM, Azar C, Brother M, et al Neuroblastoma: effect of genetic factors on prognosis and treatment. Cancer 1992;70:Suppl:1685-94
4. Roninson IB, ed. Molecular and cellular biology of multidrug resistance in tumor cells New York: Plenum Press, 1991.
5. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325:1608-14.
6. Corrias MV, Cornaglia-Ferraris P, Di Martino D, et al. Expression of multiple drug resistance gene, MDR1, and N-myc oncogene in an Italian population of human neuroblastoma patients. Anticancer Res 1990;10:897-902
7. Bourhis J, Benard J, Hartmann O, Boccon-Gibod L, Lemerle J, Riou G Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 1989;81:1401-5.
8. Goldstein LJ, Fojo AT, Ueda K, et al. Expression of the multidrug resistance, MDR1, gene in neuroblastoma J Clin Oncol 1990,8:128-36.
9. Favrot M, Combaret V, Goillot E, et al. Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer 1991;64: 233-8.
10. Nakagawara A, Kadomatsu K, Sato S, et al. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas Cancer Res 1990,50 3043-7
11. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-4.
12. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-61.
13. Kruh GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene Cancer Res 1994;54:1649-52.
14. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SPC. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 1993;53.3221-5
15. Zaman GJR, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A 1994;91:8822-6.
16. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994;54:5036-40.
17. Brodeur GM, Seeger RC, Barrett A, et al International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-81.
18. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group study. J Clin Oncol 1988;6.1271-9.
19. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma: children's cancer study group A. Cancer 1971;27:374-8.
20. Seeger RC, Brodeur GM, Sather H, et al Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313.1111-6.
21. Telford DJ, Kavallaris M, White L, Norris MD, Brian MJ, Stewart BW. Association of N-myc amplification with neuroblastoma: the Australian and New Zealand experience. J Paediatr Child Health 1992;28 58-63.
22. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73:405-16
23. Bernard JL, Philip T, Zucker JM, et al. Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma, an effective alternating non-cross-resistant regimen? J Clin Oncol 1987;5:1952-9.
24. McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin and total body irradiation J Clin Oncol 1995;13:2789-95.
25. Joshi VV, Cantor AB, Brodeur GM, et al. Correlation between morphologic and other prognostic markers of neuroblastoma: a study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer 1993;71-3173-81.
26. Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol 1991;9:789-95.
27. Nitschke R, Smith EI, Altshuler G, et al. Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:1181-8
28. Bowman LC, Castleberry RP, Altshuler G, et al Therapy based on DNA index (DI) for infants with unresectable and disseminated neuroblastoma (NB) preliminary results of the Pediatric Oncology Group "Better Risk" Study Med Pediatr Oncol 1990;18:364. abstract.
29. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1994;12:1616-20.
30. Strother D, Shuster JJ, McWilliams N, et al Results of Pediatric Oncology Group protocol 8104 for infants with stages D and DS neuroblastoma J Pediatr Hematol Oncol 1995;17:254-9.
31. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 1990;87:7160-4.
32. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992;84:1486-91.
33. Haber M, Madafiglio J, Bordow SB, et al Expression of retinoic acid-responsive genes in primary neuroblastomas. In: Evans AE, Biedler JL, Brodeur GM, D'Angio GJ, Nakagawara A, eds. Advances in neuroblastoma research 4: proceedings of the Sixth Symposium on Advances in Neuroblastoma Research held in Philadelphia, Pennsylvania, May 13-15, 1993. Vol. 385 of Progress in clinical and biological research. New York: Wiley-Liss, 1994:245-51
34. Marshall GM, Cheung B, Stacey KP, et al. Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells. Oncogene 1995;11:485-91.
35. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
36. Gilbert J, Norris MD, Haber M, Kavallaris M, Marshall GM, Stewart BW Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction. Mol Cell Probes 1993;7:227-34.
37. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54
38. Christiansen H, Sahin K, Berthold F, Hero B, Terpe H-J, Lampert F. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma Eur J Cancer 1995;31A.541-4
39. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991,9:581-91.
40. Schwab M. Molecular cytogenetics of human neuroblastoma. Biochim Biophys Acta 1992,1114:43-50.
41. Bénard J, Bourhis J, de Vathaire F, et al Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis. In: Evans AE, Biedler JL, Brodeur GM, D'Angio GJ, Nakagawara A, eds. Advances in neuroblastoma research 4: proceedings of the Sixth Symposium on Advances in Neuroblastoma Research, held in Philadelphia, Pennsylvania, May 13-15, 1993. Vol 385 of Progress in clinical and biological research. New York: Wiley-Liss, 1994.111-6.
42. Zhu Q, Center MS Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. Cancer Res 1994;54:4488-92
43. Blackwell TK, Huang J, Ma A, et al Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol 1993;13:5216-24
44. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994;54:4833-6
45. Muller M, Meijer C, Zaman GJR, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport Proc Natl Acad Sci U S A 1994;91:13033-7.
46. 4 and structurally related conjugates. J Biol Chem 1994;269:27807-10.
47. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994,54.4313-20
48. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloro-platinum(II) metabolism and ATP-dependent efflux from leukemia cells: molecular characterization of giutathione-platinum complex and its biological significance. J Biol Chem 1993;268:20116-25.
49. Gekeler V, Boer R, Ise W, Sanders KH, Schachtele C, Beck J The specific bisindolylmalcimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun 1995; 206:119-26
50. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995;208:345-52.
51. Versantvoort CHM, Broxterman HJ, Lankelma J, Feller N, Pinedo HM. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol 1994;48:1129-36.